This conference offered a comprehensive exploration of the rapidly evolving field of malignant hematology, where leading experts examined the latest advances shaping the diagnosis and treatment of hematologic malignancies. The focused program highlighted emerging data, precision medicine strategies, and innovative therapeutic approaches that are transforming care for patients with complex blood cancers. Through expert-led discussions and evidence-based insights, participants explored key developments in targeted therapies, cellular treatments, and biomarker-driven decision making across a range of hematologic malignancies. Attendees gained practical perspectives on integrating new clinical evidence into everyday practice while navigating the challenges of delivering personalized care in a rapidly advancing field.
Announcement
Photos
Powerpoint Decks
Precision in Myeloid Malignancies: Are We There Yet?
Talha Badar, MD
Mayo Clinic Jacksonville
Newly Diagnosed Fit AML: Are We Done With Intensive Chemotherapy?
Intensive Chemotherapy
Rushang Patel, MD, PhD, FACP
AdventHealth Orlando
Lower-Intensity Therapy
Jennifer Marvin-Peek, MD
MD Anderson Cancer Center
Lower-Risk MDS: Should All Patients Receive Frontline Luspatercept?
Frontline Luspatercept
Namrata Chandhok, MD
UM Sylvester Comprehensive Cancer Center
Alternative Frontline Strategies
Jonathan Feld, MD
Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
Newly Diagnosed Multiple Myeloma: Balancing Efficacy with Toxicity
Ricardo Parrondo, MD
Mayo Clinic Jacksonville
Newly Diagnosed Multiple Myeloma: Are We Done with Autologous Stem Cell Transplant?
Moving Away from Upfront Auto-SCT
Dickran Kazandjian, MD
UM Sylvester Comprehensive Cancer Center
Auto-SCT Remains Standard of Care
Omar Castaneda Puglianini, MD
Moffitt Cancer Center
First Relapse Multiple Myeloma: Teclistamab + Daratumumab vs Ciltacabtagene Autoleucel
Teclistamab + Daratumumab
Nina Nguyen, MD
Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
Ciltacabtagene Autoleucel
Ankit Kansagra, MD
TGH Cancer Institute
Relapsed/Refractory Follicular Lymphoma: Evolving the Treatment Approach
D. Alan Kerr II, MD, PhD
TGH Cancer Institute
Frontline DLBCL: Are We Done With R-CHOP?
Novel Frontline Regimens
Nikesh Shah, MD
TGH Cancer Institute
R-CHOP Remains Standard
Juan Pablo Alderuccio, MD
UM Sylvester Comprehensive Cancer Center
Frontline CLL: Doublet or Triplet Fixed-Duration Therapy?
Doublet Fixed-Duration Therapy
Jacqueline Barrientos, MD, MS
Mount Sinai Comprehensive Cancer Center
Triplet Fixed-Duration Therapy
Alan Skarbnik, MD
Novant Health Cancer Institute
Rapid-Fire Summer Oncology Conference Updates and Faculty Panel
Myeloid Updates
Jeffrey Lancet, MD
Moffitt Cancer Center
Multiple Myeloma Updates
Al-Ola Abdallah, MD
University of Kansas Medical Center
Lymphoma Updates
Julio Chavez, MD, MS
Mayo Clinic Florida
Emerging Therapies in Lymphoid Disorders
Ariel Perez Perez, MD
Baptist Health Herbert Wertheim Cancer Institute
Polycythemia Vera: When Is It Time to Move Beyond Phlebotomy?
Case 1
Aaron Sidhu, MD
Cleveland Clinic Florida
Case 2
Ruben Ruiz Vega, MD
University of Florida
Polycythemia Vera: When Is It Time to Move Beyond Phlebotomy?
Expert Discussion, Part 1
Anthony M. Hunter, MD
Winship Cancer Institute of Emory University
Expert Discussion, Part 2
Anthony M. Hunter, MD
Winship Cancer Institute of Emory University
